메뉴 건너뛰기




Volumn 88, Issue 6, 2015, Pages 1434-1441

Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angi in patients with chronic kidney disease

Author keywords

Albuminuria; Amiloride; Diuretics; Hydrochlorothiazide; RAAS blockade; Spironolactone

Indexed keywords

ALBUMIN; AMILORIDE; CREATININE; ENALAPRIL; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE;

EID: 84951570631     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.249     Document Type: Article
Times cited : (26)

References (38)
  • 1
    • 16644385307 scopus 로고    scopus 로고
    • The relationship between hyperinsulinemia, hypertension and progressive renal disease
    • El-Atat FA, Stas SN, McFarlane SI et al. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-2827
    • (2004) J Am Soc Nephrol , vol.15 , pp. 2816-2827
    • El-Atat, F.A.1    Stas, S.N.2    McFarlane, S.I.3
  • 2
    • 0032512094 scopus 로고    scopus 로고
    • Pathophysiology of progressive nephropathies
    • Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. New Engl J Med 1998; 339: 1448-1456
    • (1998) New Engl J Med , vol.339 , pp. 1448-1456
    • Remuzzi, G.1    Bertani, T.2
  • 3
    • 79953053474 scopus 로고    scopus 로고
    • Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials
    • Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499
    • (2011) Eur Heart J , vol.32 , pp. 1493-1499
    • Holtkamp, F.A.1    De Zeeuw, D.2    De Graeff, P.A.3
  • 4
    • 34248178511 scopus 로고    scopus 로고
    • Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    • Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1540-1546
    • Eijkelkamp, W.B.1    Zhang, Z.2    Remuzzi, G.3
  • 5
    • 9644294206 scopus 로고    scopus 로고
    • Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results
    • RENAAL Study Group
    • Remuzzi G, Ruggenenti P, Perna A et al; RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125
    • (2004) J Am Soc Nephrol , vol.15 , pp. 3117-3125
    • Remuzzi, G.1    Ruggenenti, P.2    Perna, A.3
  • 6
    • 4344621497 scopus 로고    scopus 로고
    • Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    • de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
    • (2004) Circulation , vol.110 , pp. 921-927
    • De Zeeuw, D.1    Remuzzi, G.2    Parving, H.H.3
  • 7
    • 2442680120 scopus 로고    scopus 로고
    • Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
    • de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
    • (2004) Kidney Int , vol.65 , pp. 2309-2320
    • De Zeeuw, D.1    Remuzzi, G.2    Parving, H.H.3
  • 8
    • 0035922444 scopus 로고    scopus 로고
    • Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes
    • Parving HH, Lehnert H, Bröchner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
    • (2001) N Engl J Med , vol.345 , pp. 870-878
    • Parving, H.H.1    Lehnert, H.2    Bröchner-Mortensen, J.3
  • 9
    • 0034113852 scopus 로고    scopus 로고
    • Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo controlled trials
    • Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo controlled trials. Am J Kidney Dis 2000; 35: 695-707
    • (2000) Am J Kidney Dis , vol.35 , pp. 695-707
    • Kshirsagar, A.V.1    Joy, M.S.2    Hogan, S.L.3
  • 10
    • 0038188560 scopus 로고    scopus 로고
    • Retarding progression of chronic renal disease: The neglected issue of residual proteinuria
    • Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261
    • (2003) Kidney Int , vol.63 , pp. 2254-2261
    • Ruggenenti, P.1    Perna, A.2    Remuzzi, G.3
  • 11
    • 34249702586 scopus 로고    scopus 로고
    • Surrogate end points for clinical trials of kidney disease progression
    • Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1: 874-884
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 874-884
    • Stevens, L.A.1    Greene, T.2    Levey, A.S.3
  • 12
    • 0036435819 scopus 로고    scopus 로고
    • Renal damage associated with proteinuria
    • Praga M, Morales E. Renal damage associated with proteinuria. Kidney Int 2002; 62: S42-S46
    • (2002) Kidney Int , vol.62 , pp. S42-S46
    • Praga, M.1    Morales, E.2
  • 13
    • 0035902622 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
    • Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
    • (2001) Ann Intern Med , vol.135 , pp. 73-87
    • Jafar, T.H.1    Schmid, C.H.2    Landa, M.3
  • 14
    • 13244298395 scopus 로고    scopus 로고
    • Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
    • Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertension 2005; 18: 44-49
    • (2005) Am J Hypertension , vol.18 , pp. 44-49
    • Sato, A.1    Hayashi, K.2    Saruta, T.3
  • 15
    • 2342559832 scopus 로고    scopus 로고
    • The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study
    • Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475
    • (2004) Diabet Med , vol.21 , pp. 471-475
    • Rachmani, R.1    Slavachevsky, I.2    Amit, M.3
  • 16
    • 24144495285 scopus 로고    scopus 로고
    • Beneficial effects of adding spironolactone to recomendad antihypertensive treatment in diabetic nephopathy: A randomized, double-masked, cross over study
    • Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recomendad antihypertensive treatment in diabetic nephopathy: a randomized, double-masked, cross over study. Diabetes Care 2005; 28: 2106-2112
    • (2005) Diabetes Care , vol.28 , pp. 2106-2112
    • Rossing, K.1    Schjoedt, K.J.2    Smidt, U.M.3
  • 17
    • 33746558934 scopus 로고    scopus 로고
    • Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker
    • Crysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 256-262
    • Crysostomou, A.1    Pedagogos, E.2    MacGregor, L.3
  • 18
    • 84903993734 scopus 로고    scopus 로고
    • Aldosterone blockade in chronic kidney disease
    • Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. Semin Nephrol 2014; 34: 307-322
    • (2014) Semin Nephrol , vol.34 , pp. 307-322
    • Hirsch, J.S.1    Drexler, Y.2    Bomback, A.S.3
  • 19
    • 72049109463 scopus 로고    scopus 로고
    • Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy
    • Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650
    • (2009) J Am Soc Nephrol , vol.20 , pp. 2641-2650
    • Mehdi, U.F.1    Adams-Huet, B.2    Raskin, P.3
  • 20
    • 38149030811 scopus 로고    scopus 로고
    • Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review
    • Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211
    • (2008) Am J Kidney Dis , vol.51 , pp. 199-211
    • Bomback, A.S.1    Kshirsagar, A.V.2    Amamoo, M.A.3
  • 21
    • 84923834917 scopus 로고    scopus 로고
    • Aldosterone antagonists for preventing the progression of chronic kidney disease
    • Bolignano D, Palmer SC, Navaneethan SD et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4: CD007004
    • (2014) Cochrane Database Syst Rev , vol.4 , pp. CD007004
    • Bolignano, D.1    Palmer, S.C.2    Navaneethan, S.D.3
  • 22
    • 72749083202 scopus 로고    scopus 로고
    • The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective?
    • Morales E, Huerta A, Gutierrez E et al. The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective?. Nefrologia 2009; 29: 421-429
    • (2009) Nefrologia , vol.29 , pp. 421-429
    • Morales, E.1    Huerta, A.2    Gutierrez, E.3
  • 23
    • 84874521311 scopus 로고    scopus 로고
    • Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
    • Morales E, Millet VG, Rojas-Rivera J et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013; 28: 405-412
    • (2013) Nephrol Dial Transplant , vol.28 , pp. 405-412
    • Morales, E.1    Millet, V.G.2    Rojas-Rivera, J.3
  • 24
    • 44049101711 scopus 로고    scopus 로고
    • Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
    • Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
    • (2008) J Am Soc Nephrol , vol.19 , pp. 999-1007
    • Vogt, L.1    Waanders, F.2    Boomsma, F.3
  • 25
    • 0031748479 scopus 로고    scopus 로고
    • The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
    • Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1682-1685
    • Buter, H.1    Hemmelder, M.H.2    Navis, G.3
  • 26
    • 84899980423 scopus 로고    scopus 로고
    • Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial
    • Holland Nephrology Study (HONEST) Group
    • Kwakernaak AJ, Krikken JA, Binnenmars SH et al; Holland Nephrology Study (HONEST) Group. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2: 385-395
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 385-395
    • Kwakernaak, A.J.1    Krikken, J.A.2    Binnenmars, S.H.3
  • 27
    • 20544471164 scopus 로고    scopus 로고
    • Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents
    • Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474-481
    • (2005) J Am Soc Nephrol , vol.16 , pp. 474-481
    • Esnault, V.L.1    Ekhlas, A.2    Delcroix, C.3
  • 28
    • 77954341674 scopus 로고    scopus 로고
    • Diuretic uptitration with half dose combined ACEI+ARB better decreases proteinuria than combined ACEI+ARB uptitration
    • Esnault VL, Ekhlas A, Nguyen JM et al. Diuretic uptitration with half dose combined ACEI+ARB better decreases proteinuria than combined ACEI+ARB uptitration. Nephrol Dial Transplant 2010; 25: 2218-2224
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 2218-2224
    • Esnault, V.L.1    Ekhlas, A.2    Nguyen, J.M.3
  • 29
    • 0037382169 scopus 로고    scopus 로고
    • Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats
    • Sepehrdad R, Chander PN, Oruene A et al. Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats. Am J Hypertens 2003; 16: 312-318
    • (2003) Am J Hypertens , vol.16 , pp. 312-318
    • Sepehrdad, R.1    Chander, P.N.2    Oruene, A.3
  • 30
    • 84862119511 scopus 로고    scopus 로고
    • Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria
    • Zhang B, Xie S, Shi W et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 2012; 27: 1746-1755
    • (2012) Nephrol Dial Transplant , vol.27 , pp. 1746-1755
    • Zhang, B.1    Xie, S.2    Shi, W.3
  • 31
    • 33845238078 scopus 로고    scopus 로고
    • Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors
    • Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446
    • (2006) J Am Soc Nephrol , vol.17 , pp. 3438-3446
    • Nagase, M.1    Yoshida, S.2    Shibata, S.3
  • 32
    • 47649085301 scopus 로고    scopus 로고
    • Aldosterone and glomerular podocyte injury
    • Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008; 12: 233-242
    • (2008) Clin Exp Nephrol , vol.12 , pp. 233-242
    • Nagase, M.1    Fujita, T.2
  • 33
    • 0031600240 scopus 로고    scopus 로고
    • Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
    • Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458
    • (1998) Hypertension , vol.31 , pp. 451-458
    • Rocha, R.1    Chander, P.N.2    Khanna, K.3
  • 34
    • 0024324630 scopus 로고
    • Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
    • Heeg JE, de Jong PE, van der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279
    • (1989) Kidney Int , vol.36 , pp. 272-279
    • Heeg, J.E.1    De Jong, P.E.2    Van Der Hem, G.K.3
  • 35
    • 79953053474 scopus 로고    scopus 로고
    • Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials
    • Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011; 32: 1493-1499
    • (2011) Eur Heart J. , vol.32 , pp. 1493-1499
    • Holtkamp, F.A.1    De Zeeuw, D.2    De Graeff, P.A.3
  • 36
    • 0037309569 scopus 로고    scopus 로고
    • Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies
    • Morales E, Valero MA, León M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327
    • (2003) Am J Kidney Dis , vol.41 , pp. 319-327
    • Morales, E.1    Valero, M.A.2    León, M.3
  • 37
    • 79960407033 scopus 로고    scopus 로고
    • An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
    • Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282-287
    • (2011) Kidney Int , vol.80 , pp. 282-287
    • Holtkamp, F.A.1    De Zeeuw, D.2    Thomas, M.C.3
  • 38
    • 3442886513 scopus 로고    scopus 로고
    • Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
    • Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
    • (2004) N Engl J Med , vol.351 , pp. 543-551
    • Juurlink, D.N.1    Mamdani, M.M.2    Lee, D.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.